Clinical-stage biotech developing next-generation DNA damage response (DDR) cancer therapies, including ATR inhibitor alnodesertib and Polθ inhibitor ART6043, plus preclinical DDRi-ADCs.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €115 M | Nov, 2025 | series-d |
Industries
Frequently Asked Questions
What industries does Artios operate in?
Artios operates in the following industries: biotechnology, pharmaceuticals, healthcare.
How much total funding has Artios raised?
Artios has raised a total of $115,000,000.
Who are the investors in Artios?
The investors in Artios are: SV Health Investors, RA Capital Management, Janus Henderson Investors, Andera Partners, Avidity Partners, EQT Life Sciences, Invus, IP Group plc, M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures, Piper Heartland, Sofinnova Partners, Schroders Capital.